Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07355218 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableLead sponsor: EMD Serono Research & Development Institute, Inc. to EMD Serono Research & Development Institute, Inc.Primary endpoints: details revised at 1 of 1 entry · Trial sites expanded: 36 → 57 locations · Eligibility criteria expanded, about 15 words · 1 moreShow 4 more changesShow less
Primary endpoints: details revised at 1 of 1 entry
Trial sites expanded: 36 → 57 locations
Eligibility criteria expanded, about 15 words
Secondary endpoints: details revised at 12 of 14 entries
MinorTrial sites expanded: 17 → 36 locationsv11
MinorTrial sites expanded: 13 → 17 locationsv10
MinorTrial sites expanded: 9 → 13 locationsv9
MinorTrial sites expanded: 4 → 9 locationsv8
Show 2 earlier versionsHide 2 earlier versions
MinorStudy sites: 3 to 4v7
MinorStudy sites: 2 to 3Start date changed from estimate of Mar 27, 2026 to Apr 1, 2026v6Show 1 more changeShow less
Start date changed from estimate of Mar 27, 2026 to Apr 1, 2026
NotableRecruitment openedStudy sites: 1 to 2 · Collaborator revisedv5Show 2 more changesShow less
NotableLead sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany to EMD Serono Research & Development Institute, Inc.Collaborator revisedv4Show 1 more changeShow less
NotableStart date: Feb 25, 2026 to Mar 27, 2026Primary and study completion dates: Mar 19, 2029 to May 25, 2029v3Show 1 more changeShow less
Primary and study completion dates: Mar 19, 2029 to May 25, 2029
MinorStudy Identification, Study Statusv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include:
Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo.
Intervention Form: Film-coated tablet.